ABOUT DANAHER LIFE SCIENCES

Every day, scientists around the world are dedicated to unraveling the mysteries of disease, discovering novel therapies and vaccines, and conducting crucial drug testing. At Danaher Life Sciences, a collection of businesses within Danaher Corporation, we play a pivotal role in facilitating these cutting-edge scientific endeavors. Our comprehensive capabilities go beyond research, enabling us to drive the development of innovative biopharmaceuticals, revolutionary cell and gene therapies, and other breakthrough treatments that propel patient health forward and enhance treatment outcomes.

                          


                        

FEATURED ARTICLES

  • Assess anti-cancer compounds' effects on organoid size and morphology with colorectal cancer organoids as well as discover automated imaging and viability assays to streamline drug screening and aid early identification.

  • Explore parallelism testing methods, including response and parameter comparison tests, with innovative software to ensure accurate results with detailed protocols for linear and non-linear regression curves.

  • Accelerate the pace of your scientific discovery with user-friendly assay kits that simplify experimental design and are paired with advanced instruments and software to enhance data quality and streamline workflows.

  • Using CRC organoids and bioprinting, explore the automation of dome assays to evaluate drug responses and delve into the insights from image-based end-point assays on the efficacy of anti-cancer treatments.

  • Automating cell culture tasks can reduce human error and free scientists from labor-intensive routines. Discover how imaging and automated systems enhance accuracy and reproducibility in cell culture processes.

  • In biopharmaceutical development, the Fc PAIA Titer assay offers a fast, cost-effective, and automatable solution for high-throughput Fc quantification to enhance efficiency, support research, and accelerate production advancements.

  • 3D organoids enhance drug toxicity prediction and are crucial for anti-cancer drug development. Examine a method using 3D mouse intestinal organoids that aims to provide vital data on intestinal toxicity.

  • Synthetic biology merges biology, engineering, and technology to create new biological systems. Explore its transformative impact on industries, sustainability, and the pioneering research driving this exciting field.

  • As climate change and resource scarcity intensify, cultivated meat emerges as a sustainable, ethical alternative to traditional farming. Discover its potential, innovations, and the industry leaders driving this revolution.

  • Explore CRISPR-Cas9's transformative potential in healthcare as well as its principles, innovations, and global applications to gain valuable insight into transforming your approach to gene editing.

  • Imagine a world where biotechnology streamlines your research. Discover automated colony pickers, UV sanitization, and high-resolution imaging to ensure efficiency and sterility in your cell lines.

  • Discover high-throughput solutions designed to accelerate the selection of high-producing mammalian cell lines and how recombinant cell lines are projected to exceed $10 billion by 2030.

  • Discover how automated 3D cell culture methods enhance efficiency and consistency in high-throughput drug screening to accelerate the discovery of new anti-cancer therapies.

  • Explore the mTOR signaling pathway and reveal how mTORC1 regulates cell growth, metabolism, and survival to ensure cellular function and adaptation to environmental cues.

  • In Alzheimer's disease, reduced VEGF levels are linked to neurodegeneration, which can offer therapeutic potential. Discover how experimental treatments show promise in reducing memory impairment and beta-amyloid deposition.

  • Recent research highlights neuroinflammation's role in AD progression, which suggests immune modulation as a potential therapeutic strategy. Learn more about neuroinflammatory processes in AD pathology.

  • Alzheimer’s disease (AD) affects 50 million people globally, causing cognitive decline. Explore the signaling pathways of amyloid beta and tau proteins, linking them to neuronal death and AD symptoms.

  • Explore how intra-tumor heterogeneity (ITH) impacts cancer progression and therapy resistance with advanced imaging platforms and custom antibody panels to reveal the spatial architecture of glioblastoma (GBM).

  • Explore recombinant antibody reagents that support the imaging of key targets within the TME and offer flexible solutions across various platforms to improve patient outcomes.

  • Select the right antibody clone by exploring enhanced validation data for top recombinant antibody clones that offer comprehensive specificity and sensitivity insights tailored to your project's unique requirements.

CONTACT INFORMATION

Danaher Life Sciences

500 Old Connecticut Path

Framingham, MA 01701

UNITED STATES